Silence Therapeutics plc (SLN)

NASDAQ: SLN · Real-Time Price · USD

14.59

-0.20 (-1.35%)

At close: Sep 4, 2026, 4:00 PM EDT

13.21

-1.38 (-9.46%)

After-hours: Sep 4, 2026, 7:53 PM EDT

Silence Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	72.05	11.28	121.33	68.79	66.05	99.57
Short-Term Investments	-	73.84	26	-	19.67	-
Cash & Short-Term Investments	72.05	85.11	147.33	68.79	85.72	99.57
Cash Growth	-36.88%	-42.23%	114.18%	-19.75%	-13.91%	94.75%
Accounts Receivable	-	-	0.97	0.29	1.1	0.45
Other Receivables	9.29	24.61	25.94	23.69	19.79	11.04
Receivables	9.29	24.61	26.91	23.98	20.9	11.49
Prepaid Expenses	-	8.93	13.12	10.39	9.88	5.83
Other Current Assets	12.94	-	-	-	-	-
Total Current Assets	94.28	118.66	187.37	103.15	116.5	116.9
Property, Plant & Equipment	1.44	1.75	1.98	2.31	2.65	2.63
Long-Term Investments	-	-	-	-	0.34	0.41
Goodwill	10.33	10.62	9.39	9.98	9.65	10.28
Other Intangible Assets	0.24	0.29	0.31	0.36	0.39	0.03
Other Long-Term Assets	0.13	0.13	3.59	3.65	-	-
Total Assets	106.41	131.44	202.64	119.45	129.53	130.25

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	12.61	4.41	3.7	3.35	3.84	5.5
Accrued Expenses	-	8.91	12.05	11.72	10.67	8.85
Current Portion of Leases	0.1	0.09	0.12	0.23	0.54	0.19
Current Income Taxes Payable	-	0.04	0.65	0.47	0.71	0.25
Current Unearned Revenue	-	0.17	0.31	6.57	10.68	5.75
Total Current Liabilities	12.71	13.61	16.82	22.34	26.44	20.54
Long-Term Leases	0.01	0.07	-	0.12	-	-
Long-Term Unearned Revenue	55.22	55.45	51.79	75	76.49	98.17
Total Liabilities	67.94	69.14	68.61	97.46	102.93	118.71

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	10.29	10.29	10.29	8.85	6.49	6.08
Additional Paid-In Capital	621.15	617.56	609.56	455.77	273.11	249.6
Retained Earnings	-592.97	-562.57	-474.04	-431.89	-317.2	-301.91
Comprehensive Income & Other	-	-2.98	-11.78	-10.73	64.19	57.78
Shareholders' Equity	38.47	62.3	134.02	21.99	26.59	11.54
Total Liabilities & Equity	106.41	131.44	202.64	119.45	129.53	130.25

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	0.11	0.16	0.12	0.35	0.54	0.19
Net Cash (Debt)	71.94	84.95	147.22	68.44	85.18	99.39
Net Cash Growth	-36.98%	-42.29%	115.09%	-19.65%	-14.29%	96.17%
Net Cash Per Share	1.52	1.80	3.18	1.85	2.65	3.35
Filing Date Shares Outstanding	47.25	47.23	47.22	46.5	35.95	29.93
Total Common Shares Outstanding	47.25	47.23	47.22	39.62	35.94	29.93
Working Capital	81.57	105.05	170.54	80.82	90.06	96.36
Book Value Per Share	0.81	1.32	2.84	0.56	0.74	0.39
Tangible Book Value	27.91	51.4	124.32	11.65	16.56	1.23
Tangible Book Value Per Share	0.59	1.09	2.63	0.29	0.46	0.04
Machinery	-	5.54	6.34	6.44	6.01	6.92

SEC Filings: 10-K · 10-Q